RUBIUS THERAPEUTICS
Rubius Therapeutics is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company was conceived and launched by Flagship VentureLabs®, the innovation foundry where a team of scientific entrepreneurs systematically evolve enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures.
RUBIUS THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.rubiustx.com
Total Employee:
101+
Status:
Active
Contact:
(617)218-1606
Email Addresses:
[email protected]
Total Funding:
445 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
NorthStar Medical Radioisotopes
NorthStar Medical Radioisotopes develops technologies and raw materials for the nuclear medicine market.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Flagship Pioneering
Flagship Pioneering investment in Series C - Rubius Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series B - Rubius Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Series A - Rubius Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-30 | Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer |
Official Site Inspections
http://www.rubiustx.com Semrush global rank: 3.46 M Semrush visits lastest month: 4.41 K
- Host name: a16e665f42988324c.awsglobalaccelerator.com
- IP address: 13.248.243.5
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Rubius Therapeutics"
Rubius Therapeutics - Crunchbase Company Profile & Funding
Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics. View contacts for Rubius Therapeutics to access new leads and …See details»
Rubius Therapeutics - LinkedIn
Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of...See details»
Rubius Therapeutics Announces Strategic Update - GlobeNewswire
Sep 13, 2022 · Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform. Initiating Cost-Saving Measures Through Corporate Restructuring; Cash …See details»
Rubius Decommission
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.See details»
Rubius Therapeutics Company Profile - Craft
Dec 29, 2023 · Rubius Therapeutics has 5 employees across 2 locations. See insights on Rubius Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Rubius Therapeutics, Inc. - Cruelty Free Investing
Rubius Therapeutics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research. …See details»
Rubius Therapeutics Announces First Patient Dosed with
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood …See details»
Rubius Therapeutics to Provide Strategic Update | BioSpace
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood …See details»
Rubius Therapeutics to Announce First Quarter 2021 Financial …
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood …See details»
Rubius Therapeutics Appoints Chief Medical Officer; …
Sep 27, 2017 · Rubius RCTs exhibit fundamentally unique biology and have been engineered to replace missing enzymes for patients living with a variety of rare diseases, to kill tumors, and upregulate or...See details»
Rubius Therapeutics to Announce Third Quarter 2021 Financial …
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood …See details»
Rubius Therapeutics, Inc. | Insights
Nov 29, 2023 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Rubius Therapeutics to Announce Fourth Quarter and Full Year …
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is using its platform to genetically …See details»
Rubius Therapeutics Announces First Patient Dosed in Phase
Apr 12, 2021 · RTX-321 is an allogeneic, off-the-shelf Red Cell Therapeutic product candidate that is engineered as an artificial antigen-presenting cell (aAPC) with a dual mechanism of …See details»
Rubius Therapeutics Announces Webcast to Review Initial Clinical …
CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering …See details»
Rubius Therapeutics Appoints Dannielle Appelhans as Chief …
CAMBRIDGE Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood …See details»
Rubius Therapeutics Announces Webcast to Review Initial
CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering …See details»
Rubius Therapeutics Announces Proposed Public Offering of …
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically …See details»
Rubius Therapeutics to Host Virtual Preclinical Pipeline
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood …See details»